{"id":"https://openalex.org/W1883583237","doi":"https://doi.org/10.1111/dom.12540","title":"Efficacy and safety of once\u2010weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once\u2010daily insulin glargine in J apanese patients with type 2 diabetes: a randomized, open\u2010label, phase III , non\u2010inferiority study","display_name":"Efficacy and safety of once\u2010weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once\u2010daily insulin glargine in J apanese patients with type 2 diabetes: a randomized, open\u2010label, phase III , non\u2010inferiority study","alternate_titles":[],"publication_year":2015,"publication_date":"2015-08-20","ids":{"openalex":"https://openalex.org/W1883583237","doi":"https://doi.org/10.1111/dom.12540","mag":"1883583237","pmid":"https://pubmed.ncbi.nlm.nih.gov/26179754","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5042081"},"language":"en","primary_location":{"id":"doi:10.1111/dom.12540","doi":"https://doi.org/10.1111/dom.12540","is_oa":true,"landing_page_url":"https://doi.org/10.1111/dom.12540","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.12540","source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1883583237"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.12540","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5067248419","display_name":"Eiichi Araki","orcid":"https://orcid.org/0000-0002-4064-7525","observed_orcids":["https://orcid.org/0000-0002-4064-7525"]},"institutions":[{"id":"https://openalex.org/I96036126","display_name":"Kumamoto University","ror":"https://ror.org/02cgss904","country_code":"JP","type":"education","lineage":["https://openalex.org/I96036126"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"E. Araki","raw_affiliation_strings":["Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan","institution_ids":["https://openalex.org/I96036126"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077189198","display_name":"Nobuya Inagaki","orcid":"https://orcid.org/0000-0001-8261-2593","observed_orcids":["https://orcid.org/0000-0001-8261-2593"]},"institutions":[{"id":"https://openalex.org/I22299242","display_name":"Kyoto University","ror":"https://ror.org/02kpeqv85","country_code":"JP","type":"education","lineage":["https://openalex.org/I22299242"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"N. Inagaki","raw_affiliation_strings":["Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan;","institution_ids":["https://openalex.org/I22299242"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014105657","display_name":"Yukio Tanizawa","orcid":"https://orcid.org/0000-0002-4742-8245","observed_orcids":["https://orcid.org/0000-0002-4742-8245"]},"institutions":[{"id":"https://openalex.org/I173915773","display_name":"Yamaguchi University","ror":"https://ror.org/03cxys317","country_code":"JP","type":"education","lineage":["https://openalex.org/I173915773"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Y. Tanizawa","raw_affiliation_strings":["Division of Endocrinology, Metabolism, Hematological Science and Therapeutics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Endocrinology, Metabolism, Hematological Science and Therapeutics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan","institution_ids":["https://openalex.org/I173915773"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065510246","display_name":"Tomonori Oura","orcid":"https://orcid.org/0000-0003-0872-8576","observed_orcids":["https://orcid.org/0000-0003-0872-8576"]},"institutions":[{"id":"https://openalex.org/I4210108315","display_name":"Eli Lilly (Japan)","ror":"https://ror.org/01sv7f575","country_code":"JP","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210108315"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"T. Oura","raw_affiliation_strings":["Eli Lilly Japan K.K. Kobe Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly Japan K.K. Kobe Japan","institution_ids":["https://openalex.org/I4210108315"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018046892","display_name":"Masakazu Takeuchi","orcid":"https://orcid.org/0000-0003-3176-3118","observed_orcids":["https://orcid.org/0000-0003-3176-3118"]},"institutions":[{"id":"https://openalex.org/I4210108315","display_name":"Eli Lilly (Japan)","ror":"https://ror.org/01sv7f575","country_code":"JP","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210108315"]}],"countries":["JP"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"M. Takeuchi","raw_affiliation_strings":["Eli Lilly Japan K.K. Kobe Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly Japan K.K. Kobe Japan","institution_ids":["https://openalex.org/I4210108315"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5082595973","display_name":"Takeshi Imaoka","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108315","display_name":"Eli Lilly (Japan)","ror":"https://ror.org/01sv7f575","country_code":"JP","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210108315"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"T. Imaoka","raw_affiliation_strings":["Eli Lilly Japan K.K. Kobe Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly Japan K.K. Kobe Japan","institution_ids":["https://openalex.org/I4210108315"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5018046892"],"corresponding_institution_ids":["https://openalex.org/I4210108315"],"apc_list":{"value":5380,"currency":"USD","value_usd":5380},"apc_paid":{"value":5380,"currency":"USD","value_usd":5380},"fwci":7.7637,"has_fulltext":true,"cited_by_count":87,"citation_normalized_percentile":{"value":0.98349903,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":99},"biblio":{"volume":"17","issue":"10","first_page":"994","last_page":"1002"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dulaglutide","display_name":"dulaglutide","score":0.9980000257492065},{"id":"https://openalex.org/keywords/insulin-glargine","display_name":"insulin glargine","score":0.9940000176429749},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9760000109672546},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.949999988079071},{"id":"https://openalex.org/keywords/sulfonylureas","display_name":"sulfonylureas","score":0.7689999938011169},{"id":"https://openalex.org/keywords/biguanides","display_name":"biguanides","score":0.9879999756813049},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.8740000128746033},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.8539999723434448},{"id":"https://openalex.org/keywords/non-inferiority","display_name":"non-inferiority","score":0.8410000205039978},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.8399999737739563},{"id":"https://openalex.org/keywords/hypoglycemia","display_name":"hypoglycemia","score":0.9929999709129333},{"id":"https://openalex.org/keywords/japanese-patients","display_name":"Japanese patients","score":0.7160000205039978},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7089999914169312},{"id":"https://openalex.org/keywords/nasopharyngitis","display_name":"nasopharyngitis","score":0.7829999923706055},{"id":"https://openalex.org/keywords/gastrointestinal-symptoms","display_name":"gastrointestinal symptoms","score":0.9229999780654907},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.3149999976158142}],"concepts":[{"id":"https://openalex.org/C2779829264","wikidata":"https://www.wikidata.org/wiki/Q21011228","display_name":"Dulaglutide","level":5,"score":0.979225754737854},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8416718244552612},{"id":"https://openalex.org/C2779920387","wikidata":"https://www.wikidata.org/wiki/Q417317","display_name":"Insulin glargine","level":4,"score":0.8042526245117188},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.6717380881309509},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6244239211082458},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5704156756401062},{"id":"https://openalex.org/C2780473172","wikidata":"https://www.wikidata.org/wiki/Q5572518","display_name":"Glycemic","level":3,"score":0.5624328255653381},{"id":"https://openalex.org/C2780533449","wikidata":"https://www.wikidata.org/wiki/Q417762","display_name":"Exenatide","level":4,"score":0.5013394355773926},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4819924235343933},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.4154631495475769},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.3628647029399872},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3616364002227783},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.31616902351379395}],"mesh":[{"descriptor_ui":"D000069036","descriptor_name":"Insulin Glargine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001645","descriptor_name":"Biguanides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D001835","descriptor_name":"Body Weight","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004763","descriptor_name":"Glucagon-Like Peptides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004763","descriptor_name":"Glucagon-Like Peptides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004763","descriptor_name":"Glucagon-Like Peptides","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005767","descriptor_name":"Gastrointestinal Diseases","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D006442","descriptor_name":"Glycated Hemoglobin","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007003","descriptor_name":"Hypoglycemia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007141","descriptor_name":"Immunoglobulin Fc Fragments","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007141","descriptor_name":"Immunoglobulin Fc Fragments","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007564","descriptor_name":"Japan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009304","descriptor_name":"Nasopharyngitis","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D013453","descriptor_name":"Sulfonylurea Compounds","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1111/dom.12540","doi":"https://doi.org/10.1111/dom.12540","is_oa":true,"landing_page_url":"https://doi.org/10.1111/dom.12540","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.12540","source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:5042081","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5042081/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Obes Metab","raw_type":"Text"},{"id":"pmid:26179754","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26179754","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, obesity & metabolism","raw_type":"Clinical Trial, Phase III"}],"best_oa_location":{"id":"doi:10.1111/dom.12540","doi":"https://doi.org/10.1111/dom.12540","is_oa":true,"landing_page_url":"https://doi.org/10.1111/dom.12540","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.12540","source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[{"id":"https://openalex.org/G7620568851","display_name":"The mechanisms of GIP secretion from enteroendocrine K cells","funder_award_id":"25293210","funder_id":"https://openalex.org/F4320334764","funder_display_name":"Japan Society for the Promotion of Science"}],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"},{"id":"https://openalex.org/F4320307781","display_name":"Sanofi","ror":"https://ror.org/027vj4x92"},{"id":"https://openalex.org/F4320309470","display_name":"Meso Scale Diagnostics","ror":"https://ror.org/05jgy0m16"},{"id":"https://openalex.org/F4320316238","display_name":"Kowa Company","ror":"https://ror.org/009z2z347"},{"id":"https://openalex.org/F4320322359","display_name":"Kyowa Hakko Kirin","ror":"https://ror.org/0586k5242"},{"id":"https://openalex.org/F4320322436","display_name":"Novo Nordisk","ror":"https://ror.org/0435rc536"},{"id":"https://openalex.org/F4320323024","display_name":"Astellas Pharma","ror":"https://ror.org/01cjash87"},{"id":"https://openalex.org/F4320327690","display_name":"Japan Diabetes Foundation","ror":"https://ror.org/002cfy541"},{"id":"https://openalex.org/F4320333624","display_name":"Eli Lilly Japan","ror":"https://ror.org/01sv7f575"},{"id":"https://openalex.org/F4320334764","display_name":"Japan Society for the Promotion of Science","ror":"https://ror.org/00hhkn466"},{"id":"https://openalex.org/F4320338262","display_name":"Daiichi Sankyo Europe","ror":"https://ror.org/01qhj1g70"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1883583237.pdf","grobid_xml":"https://content.openalex.org/works/W1883583237.grobid-xml"},"referenced_works_count":37,"referenced_works":["https://openalex.org/W49506806","https://openalex.org/W906438903","https://openalex.org/W1483095253","https://openalex.org/W1484868350","https://openalex.org/W1584571461","https://openalex.org/W1868006615","https://openalex.org/W1972057139","https://openalex.org/W1985047837","https://openalex.org/W1985743763","https://openalex.org/W1989713397","https://openalex.org/W2003589032","https://openalex.org/W2010976066","https://openalex.org/W2012425163","https://openalex.org/W2028272916","https://openalex.org/W2030546890","https://openalex.org/W2036454215","https://openalex.org/W2054981500","https://openalex.org/W2060420423","https://openalex.org/W2062098402","https://openalex.org/W2069067207","https://openalex.org/W2088001199","https://openalex.org/W2090054860","https://openalex.org/W2093375074","https://openalex.org/W2098905490","https://openalex.org/W2104252114","https://openalex.org/W2111876001","https://openalex.org/W2118805427","https://openalex.org/W2128825255","https://openalex.org/W2137352234","https://openalex.org/W2139485303","https://openalex.org/W2147679298","https://openalex.org/W2161052363","https://openalex.org/W2168959099","https://openalex.org/W2172193326","https://openalex.org/W2190748907","https://openalex.org/W2634243099","https://openalex.org/W4252564070"],"related_works":["https://openalex.org/W2888666511","https://openalex.org/W1906367066","https://openalex.org/W1951367122","https://openalex.org/W906438903","https://openalex.org/W2989874231","https://openalex.org/W2093375074","https://openalex.org/W2060420423","https://openalex.org/W2799375839","https://openalex.org/W2002401619","https://openalex.org/W2182248589"],"abstract_inverted_index":{"AIMS:":[0],"To":[1],"evaluate":[2],"0.75":[3],"mg":[4],"of":[5,105,199],"dulaglutide,":[6],"a":[7,94,101],"once-weekly":[8,227],"glucagon-like":[9],"peptide-1":[10],"receptor":[11],"agonist,":[12],"compared":[13,166,208],"with":[14,24,41,52,100,167,189,204,209,220,250],"once-daily":[15,232],"insulin":[16],"glargine":[17,137,168,210,233],"for":[18,97,234],"glycaemic":[19],"control":[20],"in":[21,87,117,125,135,144,236],"Japanese":[22,218],"patients":[23,40,219],"type":[25],"2":[26],"diabetes":[27],"(T2D).":[28],"METHODS:":[29],"In":[30,217],"this":[31],"phase":[32],"III,":[33],"randomized,":[34],"open-label,":[35],"parallel-group,":[36],"26-week":[37],"study,":[38],"361":[39],"inadequately":[42],"controlled":[43],"T2D":[44,221],"receiving":[45],"sulphonylureas":[46,224],"and/or":[47,225],"biguanides,":[48,226],"aged":[49],"\u226520":[50],"years,":[51],"glycated":[53],"haemoglobin":[54],"(HbA1c)":[55],"levels":[56],"7.0-10.0%":[57],"(53-86":[58],"mmol/mol),":[59],"inclusive,":[60],"were":[61,74,119,192],"randomized":[62],"(1":[63],":":[64],"1)":[65],"to":[66,77,231],"receive":[67],"dulaglutide":[68,127,190,205,228,242],"or":[69],"glargine.":[70],"Participants":[71],"and":[72,129,194],"investigators":[73],"not":[75],"masked":[76],"treatment":[78,142,191],"allocation.":[79],"The":[80,139,184,197],"primary":[81],"measure":[82],"was":[83,146,201,229,247],"change":[84],"from":[85],"baseline":[86],"HbA1c":[88,118,145,237],"at":[89,169,238],"26":[90,171,239],"weeks,":[91],"analysed":[92],"using":[93],"mixed-effects":[95],"model":[96],"repeated":[98],"measures,":[99],"predefined":[102],"non-inferiority":[103],"margin":[104],"0.4%.":[106],"RESULTS:":[107],"At":[108],"week":[109,170],"26,":[110],"least-squares":[111],"(LS)":[112],"mean":[113,140,173],"(standard":[114],"error)":[115],"reductions":[116],"-1.44":[120],"(0.05)%":[121,131],"[-15.74":[122],"(0.55)":[123,133],"mmol/mol]":[124,134],"the":[126,136],"group":[128],"-0.90":[130],"[-9.84":[132],"group.":[138],"between-group":[141],"difference":[143,174],"-0.54%":[147],"(95%":[148,154],"CI":[149,155,178],"-0.67,":[150],"-0.41)":[151],"[-5.90":[152],"mmol/mol":[153],"-7.32,":[156],"-4.48)];":[157],"p":[158,181,213],"<":[159,182,214],"0.001.":[160,215],"Dulaglutide":[161],"significantly":[162,202],"reduced":[163],"body":[164],"weight":[165],"(LS":[172],"-1.42":[175],"kg,":[176],"95%":[177],"-1.89,":[179],"-0.94;":[180],"0.001).":[183],"most":[185],"frequent":[186],"adverse":[187],"events":[188],"nasopharyngitis":[193],"gastrointestinal":[195,244],"symptoms.":[196],"incidence":[198],"hypoglycaemia":[200],"lower":[203],"[47/181":[206],"(26%)]":[207],"[86/180":[211],"(48%)],":[212],"CONCLUSION:":[216],"uncontrolled":[222],"on":[223],"superior":[230],"reduction":[235],"weeks.":[240],"Although":[241],"increased":[243],"symptoms,":[245],"it":[246],"well":[248],"tolerated,":[249],"an":[251],"acceptable":[252],"safety":[253],"profile.":[254]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1883583237","counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":9},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":10},{"year":2019,"cited_by_count":10},{"year":2018,"cited_by_count":14},{"year":2017,"cited_by_count":13},{"year":2016,"cited_by_count":7},{"year":2015,"cited_by_count":5}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
